Marie Scully Selected Research

Anaphylaxis (Anaphylactic Shock)

1/2022	The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura.
1/2018	Ofatumumab for TTP in a Patient with Anaphylaxis Associated with Rituximab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marie Scully Research Topics

Disease

51	Thrombotic Thrombocytopenic Purpura 05/2024 - 10/2006
16	Thrombocytopenia (Thrombopenia) 05/2024 - 03/2014
15	Thrombotic Microangiopathies 02/2023 - 01/2014
13	Thrombosis (Thrombus) 12/2022 - 01/2016
12	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 03/2024 - 11/2015
8	acquired Thrombotic thrombocytopenic purpura 01/2022 - 08/2011
7	COVID-19 12/2022 - 01/2020
7	Hemorrhage 12/2022 - 02/2016
6	Atypical Hemolytic Uremic Syndrome 06/2021 - 10/2016
5	Pre-Eclampsia (Preeclampsia) 11/2023 - 10/2018
5	Hemolytic-Uremic Syndrome 02/2023 - 01/2017
5	Hemolysis 02/2023 - 10/2018
4	Infections 12/2022 - 08/2011
4	Purpura 01/2022 - 09/2006
3	Chronic Kidney Failure (Chronic Renal Failure) 10/2021 - 01/2018
3	Headache (Headaches) 12/2020 - 11/2019
3	Stroke (Strokes) 11/2019 - 09/2006
3	Disseminated Intravascular Coagulation 01/2019 - 01/2017
2	Anaphylaxis (Anaphylactic Shock) 01/2022 - 01/2018
2	Serum Sickness 01/2022 - 01/2019
2	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022 - 01/2021
2	Intracranial Sinus Thrombosis (Sinus Thrombosis) 10/2021 - 09/2021
2	Neoplasms (Cancer) 10/2020 - 01/2019
2	Disease Progression 10/2020 - 01/2020
2	Ischemic Stroke 01/2020 - 01/2015
2	Hemolytic Anemia 01/2019 - 03/2014
2	Sepsis (Septicemia) 01/2019 - 01/2017
1	Body Weight (Weight, Body) 05/2024
1	Thrombasthenia (Glanzmann Thrombasthenia) 01/2023
1	Migraine Disorders (Migraine) 01/2023
1	Respiratory Insufficiency (Respiratory Failure) 11/2022
1	Fat Embolism 11/2022
1	Severe Acute Respiratory Syndrome 01/2022
1	Hypersensitivity (Allergy) 01/2022
1	Mood Disorders (Mood Disorder) 01/2022
1	Rare Diseases (Rare Disease) 01/2022
1	Pregnancy-Induced Hypertension (Hypertension, Pregnancy Induced) 12/2021
1	Acute Kidney Injury (Acute Renal Failure) 06/2021
1	Chronic Renal Insufficiency 06/2021
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2021
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 11/2020
1	Eclampsia 11/2020
1	Bone Marrow Failure Disorders 10/2020
1	Brain Injuries (Brain Injury) 01/2020
1	Transient Ischemic Attack 01/2020
1	Epistaxis (Nosebleed) 01/2020

Drug/Important Bio-Agent (IBA)

39	thiamine triphosphorate (TTP)IBA 05/2024 - 09/2006
11	VaccinesIBA 12/2022 - 01/2021
10	caplacizumabIBA 01/2023 - 02/2016
9	Complement System Proteins (Complement)IBA 02/2023 - 03/2014
9	Metalloproteases (Metalloproteinases)IBA 01/2023 - 02/2007
9	AntibodiesIBA 01/2022 - 02/2007
9	Rituximab (Mabthera)FDA Link 01/2022 - 02/2007
8	von Willebrand FactorIBA 11/2023 - 01/2015
8	DisintegrinsIBA 01/2023 - 02/2007
8	ThrombospondinsIBA 01/2023 - 02/2007
7	Inosine Triphosphate (ITP)IBA 03/2024 - 11/2015
6	EnzymesIBA 02/2023 - 10/2018
6	ChAdOx1 nCoV-19IBA 12/2022 - 01/2021
5	Immunoglobulin G (IgG)IBA 01/2023 - 02/2007
5	AntigensIBA 12/2022 - 02/2007
5	fibrin fragment D (D-dimer)IBA 01/2022 - 01/2021
5	Heparin (Liquaemin)FDA LinkGeneric 01/2022 - 01/2016
5	AutoantibodiesIBA 01/2021 - 02/2007
4	ravulizumabIBA 06/2021 - 01/2020
4	Complement Inactivating AgentsIBA 05/2021 - 10/2018
3	Platelet Factor 4IBA 01/2022 - 01/2021
3	eculizumab FDA Link 10/2021 - 01/2018
2	Thrombopoietin ReceptorsIBA 03/2024 - 01/2018
2	eltrombopag FDA Link 03/2024 - 01/2017
2	Monoclonal AntibodiesIBA 01/2022 - 11/2019
2	Fibrinogen (Factor I)FDA Link 01/2022 - 10/2021
2	Factor VIII (Coagulation Factor VIII)IBA 01/2022 - 10/2006
2	ofatumumab FDA Link 01/2022 - 01/2018
2	Complement C5 (Complement 5)IBA 10/2021 - 06/2021
2	AnticoagulantsIBA 01/2021 - 01/2016
2	Intravenous Immunoglobulins (IVIG)FDA Link 11/2019 - 12/2018
2	Blood Coagulation Factors (Coagulation Factor)IBA 01/2019 - 01/2018
2	Dacarbazine (DIC)FDA LinkGeneric 01/2019 - 01/2018
2	Mycophenolic Acid (Cellcept)FDA LinkGeneric 12/2018 - 11/2015
2	Complement C3a (Complement 3a)IBA 10/2016 - 03/2014
1	romiplostim FDA Link 03/2024
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2023
1	Tyrosine (L-Tyrosine)FDA Link 11/2023
1	sutimlimabIBA 01/2023
1	Immunoglobulin A (IgA)IBA 01/2023
1	ImmunosorbentsIBA 01/2022
1	BNT162 VaccineIBA 01/2022
1	obinutuzumabIBA 01/2022
1	A-factor (Streptomyces)IBA 10/2021
1	COVID-19 VaccinesIBA 09/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	C-Reactive ProteinIBA 10/2020

Therapy/Procedure

12	Therapeutics 05/2024 - 04/2012
8	Plasma Exchange 11/2022 - 02/2007
2	Aftercare (After-Treatment) 01/2023 - 01/2017
2	Catheters 01/2022 - 01/2020
1	Hemofiltration 01/2022
1	Extracorporeal Membrane Oxygenation 01/2022
1	Immunotherapy 10/2020